TABLE 2.
Treatment history for psoriasis
| Treatment history | N | n (%) unless otherwise stated |
|---|---|---|
| Topical therapy | ||
| Number of topical therapy use | ||
| 1 topical therapy | 12 (7.4%) | |
| >1 topical therapies | 126 (77.3%) | |
| None/No data | 25 (15.3%) | |
| Duration of topical therapy use (month), median (IQR) | 56 | 73.4 (118.8) |
| Previously used topical therapy | ||
| Topical corticosteroid | 131 (94.9%) | |
| Coal tar | 114 (82.6%) | |
| Vitamin D analogues | 82 (59.4%) | |
| Salicylic acid | 33 (23.9%) | |
| Mineral oil | 18 (13.0%) | |
| Calcineurin inhibitors | 14 (10.1%) | |
| Anthralin | 4 (2.9%) | |
| Olive oil | 3 (2.2%) | |
| Systemic therapy | ||
| Number of systemic therapy use | ||
| 1 systemic therapy | 39 (23.9%) | |
| 2 systemic therapies | 38 (23.3%) | |
| 3 systemic therapies | 24 (14.7%) | |
| None/No data | 62 (38.0%) | |
| Duration of systemic therapy use (month), median (IQR) | 55 | 60.0 (132.7) |
| Previously used systemic therapy | ||
| Methotrexate | 88 (87.1%) | |
| Acitretin | 54 (53.5%) | |
| Cyclosporine | 42 (41.6%) | |
| Sulfasalazine | 3 (3.0%) | |
| Biologic therapy | ||
| Number of systemic therapy use | ||
| 1 biologic therapy | 29 (17.8%) | |
| 2 biologic therapies | 5 (3.1%) | |
| 3 biologic therapies | 1 (0.7%) | |
| None/No data | 128 (78.5%) | |
| Duration of biologic therapy use (month), median (IQR) | 25 | 9.3 (28.2) |
| Previously used biologic therapy | 35 | |
| Etanercept | 10 (28.6%) | |
| Ixekizumab | 10 (28.6%) | |
| Infliximab | 8 (22.9%) | |
| Secukinumab | 6 (17.1%) | |
| Ustekinumab | 6 (17.1%) | |
| Brodalumab | 1 (2.9%) | |
| Golimumab | 1 (2.9%) |
Abbreviation: IQR, interquartile range.